The verdict
Our read at a glance.
Whether the ghrelin analog evidence, strongest for anamorelin in cancer cachexia, supports the broad appetite, muscle, and anti-aging claims made for ghrelin-pathway compounds generally.
- The signal
- Anamorelin has large randomized trials in cancer cachexia, showing gains in body weight and lean mass but limited effect on strength, and it is approved for that use in Japan. Other ghrelin-pathway compounds are investigational or unproven, and the appetite and growth-hormone effects do not by themselves establish broad benefit.
- The unknown
- Whether increasing appetite and lean mass with ghrelin analogs translates into meaningful function and outcomes, and how anamorelin's specific cancer evidence applies, if at all, to other ghrelin compounds.
- Our read
- Real appetite and lean-mass effects in a specific cancer setting, not a general muscle or anti-aging therapy. Anamorelin's cachexia evidence is genuine but narrow, and the broader ghrelin-analog claims people see online rest on much weaker ground.
The mechanism
How it works.
Ghrelin analogs are drugs designed to mimic ghrelin, the stomach-derived "hunger hormone," and they bind the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary. Activating that receptor drives two effects at once: it increases appetite and food intake, and it triggers the pituitary to release growth hormone. Anamorelin, the most developed of these, uses this mechanism to counter the appetite loss and muscle wasting of cancer cachexia, but raising appetite and growth hormone is not the same as proving function or survival benefit, so its effect on strength and outcomes is the real question.
Safety & regulatory boundary
The consequential part.
Among ghrelin analogs, only anamorelin has a specific approval, and only in some countries for cancer cachexia. Other ghrelin-pathway compounds are investigational or sold as research chemicals of uncertain identity. Raising appetite and growth hormone is not free of risk, and a cancer-cachexia approval does not validate muscle, appetite, or anti-aging claims for ghrelin analogs in general.
What's next
What we're watching.
Wider regulatory decisions on anamorelin, outcome data beyond weight and lean mass, and any trials of other ghrelin-pathway compounds.
Context
Why this is discussed.
Ghrelin analogs draw attention because the ghrelin pathway drives both appetite and growth hormone, connecting serious cancer-cachexia drugs to the gray-market muscle and appetite scene.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2/PHASE3 · ACTIVE_NOT_RECRUITING · 2018-11-27
ClinicalTrials.gov · PHASE2 · TERMINATED · 2023-04-01
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2017-02-08
ClinicalTrials.gov · PHASE3 · COMPLETED · 2019-05-06
ClinicalTrials.gov · PHASE3 · COMPLETED · 2019-03-05
ClinicalTrials.gov · PHASE1 · COMPLETED · 2019-12-05
ClinicalTrials.gov · PHASE2 · TERMINATED · 2012-06
ClinicalTrials.gov · PHASE3 · COMPLETED · 2011-07
Indexed literature (PubMed)12
Patadia P et al. · J Clin Endocrinol Metab · 2024
Temel JS et al. · Lancet Oncol · 2016
Nishie K et al. · Drugs Today (Barc) · 2022
Dawson-Hughes B et al. · J Clin Endocrinol Metab · 2024
Zhang H et al. · Expert Opin Pharmacother · 2015
Esposito A et al. · Cancer Treat Rev · 2015
Beheshti S et al. · Epilepsy Res · 2023
Dev R et al. · Curr Oncol Rep · 2024
Tack J et al. · Curr Opin Gastroenterol · 2010
Dehkhoda F et al. · Mol Cell · 2025
Bai Y et al. · Support Care Cancer · 2017
Yanagimoto Y et al. · Gastric Cancer · 2025
Keep reading